Stock TRVI TREVI THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Delayed Nasdaq
Other stock markets
 02:17:15 2024-05-29 pm EDT 		5-day change 1st Jan Change
2.55 USD -0.39% Intraday chart for Trevi Therapeutics, Inc. -3.77% +90.30%
May. 07 Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07 Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Trevi Therapeutics to Participate in Upcoming Conferences
PR
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
PR
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
PR
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
AQ
Trevi Therapeutics to Participate in Upcoming April Events
PR
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
PR
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
PR
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
PR
Trevi Therapeutics to Participate in Upcoming March Events
PR
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR
Trevi Therapeutics Provides Business Updates
PR
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis
AQ
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
PR
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
PR
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio for Refractory Chronic Cough
AQ
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough
PR
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
PR
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio in Prurigo Nodularis
AQ
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
PR
Trevi Therapeutics to Participate in Upcoming September Events
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRVI Stock
  4. News Trevi Therapeutics, Inc.
  5. Press Releases